MX2020011665A - Sal de adicion de agonista de receptor s1p1 y forma cristalina de la misma, y composicion farmaceutica. - Google Patents
Sal de adicion de agonista de receptor s1p1 y forma cristalina de la misma, y composicion farmaceutica.Info
- Publication number
- MX2020011665A MX2020011665A MX2020011665A MX2020011665A MX2020011665A MX 2020011665 A MX2020011665 A MX 2020011665A MX 2020011665 A MX2020011665 A MX 2020011665A MX 2020011665 A MX2020011665 A MX 2020011665A MX 2020011665 A MX2020011665 A MX 2020011665A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical composition
- addition salt
- crystal form
- receptor agonist
- crystalline form
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
En la presente solicitud se divulga una forma salina y una forma cristalina del fármaco ácido 1-{2-fluoro-4-[5-(4-isobutilfenil)-1, 2,4-oxadiazol-3-il]bencil}-3-azetidinacarboxílico (fórmula A) contra una enfermedad o síntoma mediado por el receptor S1P1. En la presente solicitud se divulga también un método de preparación de la forma salina o la forma cristalina, una composición farmacéutica de la forma salina o la forma cristalina, así como el uso de la forma salina o la forma cristalina en la preparación de un medicamento para el tratamiento y/o la prevención de una enfermedad o síntoma mediado por el receptor S1P1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2018/085617 WO2019210511A1 (zh) | 2018-05-04 | 2018-05-04 | 一种s1p1受体激动剂的加成盐及其晶型和药物组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020011665A true MX2020011665A (es) | 2021-01-20 |
Family
ID=68387039
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020011665A MX2020011665A (es) | 2018-05-04 | 2018-05-04 | Sal de adicion de agonista de receptor s1p1 y forma cristalina de la misma, y composicion farmaceutica. |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11512078B2 (es) |
| EP (2) | EP4353719B1 (es) |
| JP (3) | JP7275253B2 (es) |
| KR (2) | KR102672632B1 (es) |
| AU (1) | AU2018421487B2 (es) |
| CA (1) | CA3099196A1 (es) |
| ES (1) | ES2978392T3 (es) |
| IL (3) | IL278464B2 (es) |
| MX (1) | MX2020011665A (es) |
| SG (1) | SG11202010969UA (es) |
| WO (1) | WO2019210511A1 (es) |
| ZA (1) | ZA202007347B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4353719B1 (en) * | 2018-05-04 | 2025-12-24 | Connect Biopharma HongKong Limited | Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition |
| CA3201000A1 (en) * | 2020-11-09 | 2022-05-12 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7199142B2 (en) * | 2002-06-17 | 2007-04-03 | Merck & Co., Inc. | 1-((5-aryl-1,2,4-oxadiazol-3-yl) benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl) pyrrolidine-3-carboxylates as edg receptor agonists |
| AU2003279915A1 (en) | 2002-10-15 | 2004-05-04 | Merck And Co., Inc. | Process for making azetidine-3-carboxylic acid |
| CN103450171B (zh) * | 2013-09-22 | 2015-07-08 | 苏州康乃德生物医药有限公司 | 一种免疫调节化合物、其用途和包含其的药物组合物 |
| CN105315266B (zh) * | 2014-08-01 | 2019-10-01 | 苏州康乃德生物医药有限公司 | 1-{2-氟-4-[5-(4-异丁基苯基)-1,2,4-噁二唑-3-基]-苄基}-3-吖丁啶羧酸的晶型 |
| CN105348276B (zh) | 2014-08-22 | 2020-05-26 | 苏州康乃德生物医药有限公司 | 1-{2-氟-4-[5-(4-异丁基苯基)-1,2,4-噁二唑-3-基]-苄基}-3-吖丁啶羧酸的合成方法 |
| CN108299412B (zh) * | 2017-01-11 | 2021-02-09 | 苏州康乃德生物医药有限公司 | 一种s1p1受体激动剂的加成盐及其晶型和药物组合物 |
| EP4353719B1 (en) | 2018-05-04 | 2025-12-24 | Connect Biopharma HongKong Limited | Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition |
-
2018
- 2018-05-04 EP EP24155906.1A patent/EP4353719B1/en active Active
- 2018-05-04 US US17/052,160 patent/US11512078B2/en active Active
- 2018-05-04 AU AU2018421487A patent/AU2018421487B2/en active Active
- 2018-05-04 MX MX2020011665A patent/MX2020011665A/es unknown
- 2018-05-04 JP JP2021510499A patent/JP7275253B2/ja active Active
- 2018-05-04 KR KR1020207034174A patent/KR102672632B1/ko active Active
- 2018-05-04 IL IL278464A patent/IL278464B2/en unknown
- 2018-05-04 CA CA3099196A patent/CA3099196A1/en active Pending
- 2018-05-04 SG SG11202010969UA patent/SG11202010969UA/en unknown
- 2018-05-04 EP EP18917186.1A patent/EP3792258B1/en active Active
- 2018-05-04 ES ES18917186T patent/ES2978392T3/es active Active
- 2018-05-04 KR KR1020247018420A patent/KR20240094023A/ko active Pending
- 2018-05-04 WO PCT/CN2018/085617 patent/WO2019210511A1/zh not_active Ceased
-
2020
- 2020-11-25 ZA ZA2020/07347A patent/ZA202007347B/en unknown
-
2022
- 2022-10-06 US US17/961,270 patent/US12202822B2/en active Active
-
2023
- 2023-02-17 JP JP2023023091A patent/JP7651198B2/ja active Active
-
2024
- 2024-05-01 IL IL312512A patent/IL312512B1/en unknown
- 2024-12-11 US US18/977,539 patent/US20250320200A1/en active Pending
-
2025
- 2025-03-06 JP JP2025035420A patent/JP2025074350A/ja active Pending
- 2025-09-29 IL IL323665A patent/IL323665A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL278464A (es) | 2021-03-01 |
| CA3099196A1 (en) | 2019-11-07 |
| EP3792258A1 (en) | 2021-03-17 |
| JP2025074350A (ja) | 2025-05-13 |
| US12202822B2 (en) | 2025-01-21 |
| KR20240094023A (ko) | 2024-06-24 |
| IL312512B1 (en) | 2025-11-01 |
| EP4353719A1 (en) | 2024-04-17 |
| EP3792258A4 (en) | 2021-10-06 |
| SG11202010969UA (en) | 2020-12-30 |
| JP2021532165A (ja) | 2021-11-25 |
| IL323665A (en) | 2025-11-01 |
| ZA202007347B (en) | 2021-10-27 |
| EP3792258B1 (en) | 2024-02-07 |
| IL278464B2 (en) | 2024-10-01 |
| KR102672632B1 (ko) | 2024-06-07 |
| US20210230152A1 (en) | 2021-07-29 |
| KR20210019999A (ko) | 2021-02-23 |
| AU2018421487B2 (en) | 2024-09-12 |
| AU2018421487A1 (en) | 2020-12-17 |
| US20230050777A1 (en) | 2023-02-16 |
| US20250320200A1 (en) | 2025-10-16 |
| US11512078B2 (en) | 2022-11-29 |
| WO2019210511A1 (zh) | 2019-11-07 |
| JP7651198B2 (ja) | 2025-03-26 |
| JP2023062091A (ja) | 2023-05-02 |
| ES2978392T3 (es) | 2024-09-11 |
| JP7275253B2 (ja) | 2023-05-17 |
| BR112020022429A2 (pt) | 2021-02-09 |
| IL278464B1 (en) | 2024-06-01 |
| EP4353719B1 (en) | 2025-12-24 |
| IL312512A (en) | 2024-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014012815A2 (pt) | derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doença | |
| AR109300A2 (es) | Formas cristalinas del ácido 3-[5-(2-fluorofenil)-[1,2,4]oxadiazol-3-il]-benzoico | |
| CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| GT200600445A (es) | Formas de presentación farmaceuticas solidas de administración oral con liberacion rapida del principio activo. | |
| BR112015003188A2 (pt) | Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
| MX2015017307A (es) | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington. | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| EA201691789A1 (ru) | Фармацевтические композиции и соли 1,2,4-оксадиазолбензойной кислоты | |
| BR112015029401A8 (pt) | derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas | |
| BR112016015763B8 (pt) | preparação farmacêutica incluindo composto de ácido piridilaminocético, e, uso da mesma | |
| JP2014139255A5 (es) | ||
| WO2018005801A3 (en) | Novel non-systemic tgr5 agonists | |
| MX2017004772A (es) | Composiciones y métodos para la administración fisiológica utilizando cannabidiol. | |
| CO2019006652A2 (es) | Amidas aromáticas de ácidos carboxílicos como antagonistas del receptor de bradiquinina b1 | |
| MX2017016862A (es) | Composicion farmaceutica estable para administracion oral. | |
| MX2020011665A (es) | Sal de adicion de agonista de receptor s1p1 y forma cristalina de la misma, y composicion farmaceutica. | |
| CL2020000601A1 (es) | Composición farmacéutica. | |
| BR112012020377A8 (pt) | utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial | |
| HK1203394A1 (en) | Ghrelin receptor agonists for the treatment of achlorhydria | |
| MX2019015927A (es) | Composiciones para administración de fármacos y métodos de uso de las mismas. | |
| AR098832A1 (es) | Uso de laquinimod para retrasar la progresión de la enfermedad de huntington | |
| PH12019502767A1 (en) | Oral pharmaceutical formulations of remogliflozin | |
| RU2013147196A (ru) | Агонист рецептора 5-нт4 в качестве прокинетического агента | |
| TN2016000179A1 (en) | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor. |